Aneel K Aggarwal, PhD Email Aneel Aggarwal
- PROFESSOR | Pharmacological Sciences
- PROFESSOR | Oncological Sciences
Dr. Aggarwal is an internationally recognized structural biologist, who earned his PhD in biophysics at Kings College, University of London, in 1984. From 1985 to 1987, Dr. Aggarwal participated in a NATO research fellowship and was also a postdoctoral fellow in the Department of Biochemistry and Molecular Biology at Harvard University. He then became an Assistant Professor at Columbia University before joining the Mount Sinai Medical School. He is currently a Professor in the Department of Structural & Chemical Biology and holds an Endowed Chair as the Mount Sinai Professor in Structural Biology.
DNA Repair, DNA Replication, Structural Biology, Transcription Factors, Translation
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Genetics and Data Science [GDS], Pharmacology and Therapeutics Discovery [PTD]
PhD, Kings College, University of London
, Harvard University
Dean’s Award for Excellence in Basic Science Research
Faculty Council Award for Academic Excellence
Mount Sinai Professor in Structural Biology (Endowed Chair)
The Doctor Harold and Golden Lamport Award for Excellence in Basic Science Research
Irma T. Hirschl Career Scientist Award
Basil O'Connor Starter Scholar Research Award
EMBO Long-term Fellowship (Declined)
The North Atlantic Treaty Organization (NATO) Research Fellowship
Science and Engineering Research Council (SERC) of Great Britain Studentship
Protein-nucleic acid interactions
We use a variety of structural tools to uncover how enzymes, and transcription and translation regulators interact with nucleic acids to affect cellular development and disease outcome. We study how such proteins locate, bind, and move on their DNA or RNA sites, and, then use that knowledge to create enzymes with new specificities and obtain a molecular understanding for how genes are regulated. We are also interested in learning how cells cope with the effects of DNA damage. In particular, we investigate how a set of specialized DNA polymerases can bypass DNA damage during replication and how mutations in them can lead to cancer.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Aggarwal during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Onconova Therapeutics, Inc.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Celgene Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.